SWOG clinical trial number
E2496

Randomized Phase III Trial of ABVD Versus Stanford V +/- Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease with 0-2 Risk Factors

Closed
Phase
Published
Abbreviated Title
HODGKIN'S: ABVD +/- IFR vs. Stanford V +/- IFR
Activated
06/15/1999
Closed
06/15/2006
Participants
NCORP, Members, Medical Oncologists, Radiation Oncologists, Pathologists

Research committees

Lymphoma

Treatment

Prednisone Vincristine Bleomycin Doxorubicin DTIC Vinblastine Sulfate VP-16 Mustard Radiation Therapy ABVD RT

Eligibility Criteria Expand/Collapse

Previously untreated histologically proven extensive (Stage I-IIA/B) or advanced (Stage III-IV) Hodgkin's disease; >= 16 y.o.; no known HIV; no prior chemo. or RT; WBC >= 4,000/mm3; platelets >= 100,000/mm3; creatinine >= 2.0mg/dl; bilirubin >= 5.0mg/dl; if marrow is involved - hematologic parameters do not apply; ejection fraction recommended for patients >= 50 y.o. with history of cardiac disease.

Publication Information Expand/Collapse

2018

Outcomes in adolescents and young adults (AYA) with hodgkin lymphoma (HL) treated on US cooperative group protocols: an adult intergroup (E2496) and Children’s Oncology Group (COG AHOD 0031) comparative analysis

TO Henderson;SK Parsons;K Wroblewski;L Chen;F Hong;SM Smith;J McNeer;R Advani;R Gascoyne;LS Constine;S Horning;N Bartlett;B Shah;JM Connors;J Leonard;B Kahl;K Kelly;C Schwartz;H Li;JW Friedberg;CL Friedman;LI Gordon;AM Evens Cancer, 2018 Jan 1;124(1):136-144; Sep 13. doi: 10.1002/cncr.30979. [Epub ahead of print]

PMid: PMID28902390 | PMC number: PMC5735034

2017

Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era

S Mantha;DA Goldman;SM Devlin;J Lee;D Zannino;M Collins;D Douer;HJ Iland;MR Litzow;EM Stein;F Appelbaum;RA Larson;R Stone;B Powell;S Geyer;K Laumann;JM Rowe;H Erba;S Coutre;M Othus;J Park;PH Wiernik;M Tallman Blood Mar 30;129(13):1763-1767

PMid: PMID28082441 | PMC number: PMC5374291

2016

Serum biomarkers predict outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial

JA Kanakry;F Hong;O Martinez-Maza;SJ Horning;LI Gordon;RD Gascoyne;LL Gellert;M Lemas;B Cheson;R Advani;B Pohlman;L Teston;VP Kenkre;JN Winter;P Stiff;J Tuscano;JW Friedberg;J Polikoff;LM Dreosti;JP Kuebler;S Robinson;DS Morgan;RI Fisher;N Bartlett;P Laneuville;B Kahl;RF Ambinder Blood 128:2992; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster

2015

Randomized phase III trial comparing ABVD plus radiotherapy with the Stanford V regimen in patients with stage I or II locally extensive, bulky mediastinal hodgkins lymphoma: a subset analysis of the North American Intergroup E2496 trial

R Advani;F Hong;RI Fisher;N Bartlett;S Robinson;R Gascoyne;H Wagner;P Stiff;B Cheson;D Stewart;LI Gordon;B Kahl;J Friedberg;KA Blum;TM Habermann;J Tuscano;RT Hoppe;SJ Horning Journal of Clinical Oncology Jun 10;33(17):1936-1942

PMid: PMID25897153 | PMC number: PMC4451176

Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era

CS Diefenbach;H Li;LI Gordon;RI Fisher;NL Bartlett;RM Crump;R Gascoyne;H Wagner;PJ Stiff;BD Cheson;D Stewart;BS Kahl;JW Friedberg;KA Blum;TM Habermann;JM Tuscano;RT Hoppe;SJ Horning;RH Advani British Journal of Haematology Nov;171(4):530-538

PMid: PMID26343802 | PMC number: PMC4881845

2014

The role of body mass index in survival outcome for lymphoma patients: US intergroup experience

F Hong;TM Habermann;LI Gordon;H Hochster;R Gascoyne;VA Morrison;RI Fisher;NL Bartlett;PJ Stiff;BD Cheson;M Crump;SJ Horning;BS Kahl Annals of Oncology 25(3):669-674

PMid: PMID24567515; PMC4433526

2013

Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced stage classical hodgkin lymphoma

DW Scott;FC Chan;F Hong;S Rogic;K Tan;B Meissner;S Ben-Neriah;M Boyle;R Kridel;A Telenius;B Woolcock;P Farinha;RI Fisher;L Rimsza;NL Bartlett;LE Shepherd;RH Advani;JM Connors;B Kahl;LI Gordon;SJ Horning;R Gascoyne Journal of Clinical Oncology 31(6):692-700;

PMid: PMID23182984 | PMC number: PMC3574267

A randomized phase III trial of ABVD vs. Stanford V +/- radiation therapy in locally extensive and advanced stage hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)

L Gordon;F Hong;RI Fisher;NL Bartlett;JM Connors;R Gascoyne;H Wagner;P Stiff;B Cheson;M Gospodarowicz;R Advani;B Kahl;J Friedberg;K Blum;T Habermann;J Tuscano;RT Hoppe;SJ Horning Journal of Clinical Oncology 31(6):684-691;

PMid: PMID23182987 | PMC number: PMC3574266

Plasma Epstein-Barr viral DNA as a marker of tumor response in Hodgkin lymphoma

JA Kanakry;H Li;LL Gellert;MV Lemas;W Hsieh;F Hong;KL Tan;R Gascoyne;LI Gordon;RI Fisher;NL Bartlett;P Stiff;B Cheson;R Advani;L Rimsza;B Kahl;SJ Horning Blood 121(18):3547-3553;

PMid: PMID23386127 | PMC number: PMC3643756

The efficacy and tolerability of ABVD and Stanford V in older hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496

AM Evens;F Hong;L Gordon;RI Fisher;P Stiff;T Miller;N Bartlett;J Connors;R Gascoyne;H Wagner;M Gospodarowicz;B Cheson;R Advani;R Hoppe;B Kahl;S Horning British Journal of Haematology 161(1):76-86;

PMid: PMID23356491 | PMC number: PMC3906856

Patterns of failure (POF) in a randomized phase III trial of ABVD vs. Stanford V +/- radiation therapy in locally extensive and advanced stage hodgkin's lymphoma (HL): an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)

H Wagner;LI Gordon;F Hong;TJ Fitzgerald;F Laurie;RI Fisher;N Bartlett;J Connors;R Gascoyne;P Stiff;B Cheson;M Gospodarowicz;R Advani;B Kahl;J Friedberg;K Blum;T Habermann;J Tuscano;R Hoppe;SJ Horning Hematological Oncology 31(suppl.1):abstr. #256, p.182; Int'l Conference on Malignant Lymphoma (June 19-22, 2013, Lugano, Switzerland), poster presentation;

Prospective evaluation of the utility of the international prognostic score (IPS) for patients with advanced hodgkin lymphoma (HL) treated with contemporary therapy: results from US intergroup trial E2496

CS Diefenbach;L Hong;LI Gordon;RI Fisher;NL Bartlett;JM Connors;RD Gascoyne;H Wagner;P Stiff;B Cheson;M Gospodarowicz;BS Kahl;JW Friedberg;KH Blum;TM Habermann;JM Tuscano;RT Hoppe;SJ Horning;R Advani Haematologica 98(supplement 2):P010;CS, p.4; International Symposium on Hodgkin Lymphoma (Oct.12-15, 2013, Cologne, Germany), poster presenttion;

The role of body mass index in survival outcome for lymphoma patients: an Eastern Cooperative Oncology Group Experience

F Hong;TM Habermann;LI Gordon;H Hochster;R Gascoyne;RI Fisher;N Bartlett;P Stiff;B Cheson;M Crump;S Horning;B Kahl Blood 122:3060; American Society of Hematology annual meeting (Dec 7-10, 2013), poster;

Evaluation of a novel 3 factor prognostic score (PS-3) for patients with advanced Hodgkin lymphoma (HL) treated on US Intergroup E2496

CS Diefenbach;H Li;LI Gordon;RI Fisher;NL Bartlett;M Crump;RD Gascoyne;H Wagner;P Stiff;B Cheson;D Stewart;B Kahl;J Friedberg;K Blum;T Habermann;JM Tuscano;R Hoppe;SJ Horning;R Advani Blood 122:4277; American Society of Hematology annual meeting (Dec 7-10, 2013, New Orleans, LA), poster;

2012

Tumor-associated macrophages predict inferior outcomes in locally advanced and advanced stage classical Hodgkins lymphoma - a correlative study from the E2496 intergroup trial http://www.abstracts2view.com/uscap12/view.php?nu=USCAP12L_1568

KL Tan;DW Scott;F Hong;SJ Horning;RI Fisher;N Bartlett;L Shepherd;JM Connors;BS Kahl;LI Gordon;C Steidl;R Gascoyne United States and Canadian Academy of Pathology, abst. #1568; poster presentation;

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 intergroup trial

KL Tan;DW Scott;F Hong;BS Kahl;RI Fisher;N Bartlett;R Advani;R Buckstein;L Rimsza;J Connors;C. Steidl;L Gordon;S Horning;R Gascoyne Blood 120(16):3280-3287

PMid: PMID22948049 | PMC number: PMC3476539

2011

Patterns of failure in patients with stage I/II bulky mediastinal hodgkins lymphoma (HL) treated with ABVD + radiotherapy or the Stanford V regimen in the randomized phase III North American Intergroup trial: E2496

R Advani;F Hong;L Gordon;RD Gascoyne;H Wagner;RT Hoppe;RI Fisher;L Bartlett;JM Connors;BS Kahl;P Stiff;BD Cheson;M Gospodarowicz;JW Friedberg;KA Blum;TM Habermann;JM Tuscano;SJ Horning Blood 118(21):abstract 1603; American Society of Hematology Annual Meeting, poster presenation

A gene expression signature in diagnostic formalin fixed paraffin embedded tissue predicts overall survival in locally advanced and advanced stage classical hodgkin lymphoma - a correlative study from the E2496 intergroup trial

DW Scott;FC Chan;S Rojic;K Tan;B Meissner;P Farinha;S Horning;RI Fisher;NL Bartlett;LE Shepherd;JM Connors;AB de Sousa;BS Kahl;LI Gordon;C Steidl;RD Gascoyne Blood 118(21):abstract 430; American Society of Hematology Annual Meeting, oral presentation;

2010

A randomized phase III trial of ABVD vs. Stanford V +/- radiation therapy in locally extensive and advanced stage hodgkin's lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)

L Gordon;F Hong;RI Fisher;N Bartlett;JM Connors;R Gascoyne;H Wagner;P Stiff;B Cheson;M Gospodarowicz;R Advani;B Kahl;J Friedberg;K Blum;T Habermann;J Tuscano;R Hoppe;R Horning Blood 116:abst.#415; American Society of Hematology 2010 Annual Meeting; oral

Other Clinical Trials

SWOG Clinical Trial Number
S2308

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma

Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131